Jonathan Jay Mazelsky’s recent SEC Form 4 activity paints a clear picture of a director monetizing equity positions rather than adding new exposure. Across 85 filings spanning three companies, Mazelsky has executed zero open-market purchases while recording approximately $40.7 million in total sales. The overwhelming majority of that selling occurred on February 26, 2026, when he disposed of shares in IDEXX Laboratories (IDXX) across 13 separate transactions. Those sales ranged from roughly $662,000 to $2.4 million each, cumulatively exceeding $13.3 million on that single day. The sales were paired with an option exercise valued at about $3.3 million, a mechanical transaction that supplied the shares sold, along with a smaller exercise worth roughly $99,600 the following day.
The pattern is consistent with portfolio diversification rather than a directional bet. Mazelsky’s recent activity in Dentsply Sirona (XRAY) has been limited to compensation-related grants and awards, including a $101,400 grant on June 12, 2026, and smaller awards in January, March, and June. A July 1, 2026, award in Insulet (PODD) carried no reported value. Notably, his most recent 13 filings contain no open-market buys, and the only cash-generating events are the February IDXX sales and a tax-withholding transaction (code “F”) worth roughly $576,000 on February 14, 2026. The absence of any “P” transactions across the entire filing history suggests Mazelsky is not using personal capital to accumulate shares in any of the three companies, despite receiving ongoing equity compensation.
AI-assisted summary